What is Leerink Partnrs’ Estimate for INSP FY2024 Earnings?

Inspire Medical Systems, Inc. (NYSE:INSP) – Equities research analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for shares of Inspire Medical Systems in a report released on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of $1.37 for the year, down from their prior estimate of $1.38. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $1.33 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ Q2 2025 earnings at $0.40 EPS, Q3 2025 earnings at $0.47 EPS, Q4 2025 earnings at $1.10 EPS, FY2025 earnings at $1.73 EPS and FY2026 earnings at $2.62 EPS.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.54. The company had revenue of $203.20 million for the quarter, compared to analysts’ expectations of $197.59 million. Inspire Medical Systems had a return on equity of 5.30% and a net margin of 4.37%. The firm’s revenue for the quarter was up 32.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.29) earnings per share.

Several other analysts have also commented on INSP. Bank of America upgraded Inspire Medical Systems from a “neutral” rating to a “buy” rating and increased their price objective for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Royal Bank of Canada reiterated an “outperform” rating and set a $260.00 price objective on shares of Inspire Medical Systems in a report on Tuesday, November 5th. Truist Financial reiterated a “buy” rating and set a $240.00 price objective (up previously from $217.00) on shares of Inspire Medical Systems in a report on Monday, September 30th. Robert W. Baird upped their target price on Inspire Medical Systems from $240.00 to $252.00 and gave the company an “outperform” rating in a research report on Tuesday, November 5th. Finally, Wells Fargo & Company increased their price target on Inspire Medical Systems from $187.00 to $198.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $233.58.

Inspire Medical Systems Stock Performance

Shares of NYSE INSP opened at $193.85 on Wednesday. The firm has a market capitalization of $5.81 billion, a price-to-earnings ratio of 181.17 and a beta of 1.36. The stock has a 50 day moving average price of $198.72 and a 200 day moving average price of $175.85. Inspire Medical Systems has a 52-week low of $123.00 and a 52-week high of $257.40.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. SouthState Corp acquired a new position in shares of Inspire Medical Systems during the second quarter worth about $27,000. True Wealth Design LLC acquired a new position in shares of Inspire Medical Systems during the third quarter worth about $30,000. Farther Finance Advisors LLC increased its stake in shares of Inspire Medical Systems by 1,158.3% during the third quarter. Farther Finance Advisors LLC now owns 151 shares of the company’s stock worth $32,000 after acquiring an additional 139 shares during the period. GAMMA Investing LLC increased its stake in shares of Inspire Medical Systems by 559.3% during the third quarter. GAMMA Investing LLC now owns 178 shares of the company’s stock worth $38,000 after acquiring an additional 151 shares during the period. Finally, Quarry LP increased its stake in shares of Inspire Medical Systems by 105.4% during the second quarter. Quarry LP now owns 343 shares of the company’s stock worth $46,000 after acquiring an additional 176 shares during the period. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Shawn Mccormick sold 800 shares of Inspire Medical Systems stock in a transaction on Monday, September 9th. The shares were sold at an average price of $220.00, for a total transaction of $176,000.00. Following the completion of the sale, the director now directly owns 23,140 shares of the company’s stock, valued at approximately $5,090,800. The trade was a 3.34 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.10% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.